Stay updated with breaking news from Treating Recurrent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.
Despite initial promise, combining lenalidomide with cediranib didn't improve progression-free survival in differentiated thyroid cancer (DTC).
Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.